CTLA4 and melanoma: The first ICI approved by the Food and Drug Administration (FDA) was the drug ipilimumab (cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitor), which was approved for the treatment of melanoma in 2011 [2].